Skip to main content

Table 2 Biomarker analyses

From: A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol

Compartment

Biomarker

Endpoint

Blood

➢ PR3 ANCA (ELISA)

➢ Lymphocyte immunophenotyping (flow cytometry)

➢ B cell receptor clonality, B cell and T cell functional assays, and whole blood transcriptomic analysis

➢ BAFF protein, BAFF-belimumab complex and cytokines

Primary

Secondary

Exploratory

Exploratory

Urine

➢Lymphocyte immunophenotyping (flow cytometry)

➢Proteome analysis

Exploratory

Exploratory

Tissue biopsies (subset of patients only)

➢Lymphocyte immunophenotyping (flow cytometry)

➢Single cell RNA sequencing

Exploratory

Exploratory